Authors
Latest:
Radiotherapy in the Modern Era in the Management of Langerhans Cell HistiocytosisIntensity-modulated radiotherapy reduces the mean radiation dose delivered to critical normal structures and should be considered in Langerhans cell histiocytosis treatment when radiotherapy is indicated, particularly given the expected, long-term survival of these patients.
Latest:
Mining the Pipeline: Leading Investigational Products and Areas of Unmet NeedThe oncology pipeline is crowded, despite the fact that the agents in development target a broad range of tumor types.
Latest:
Extending the Promise of Immunotherapy to Pancreatic CancerStephanie K. Dougan, PhD, assistant professor, microbiology and immunobiology, Division of Immunology, Harvard Medical School, researcher, Dana-Farber Cancer Institute, discusses ways to extend the promise of immunotherapy to the field of pancreatic cancer.
Latest:
Daily and Cumulative Dose Recalculation and in Vivo Verification for Helical TomoTherapy: Multicenter ValidationRapid advances in the technological development of precise and conformal radiation therapy and its incorporation into the clinic have generally outpaced our ability to test these technologies in a clinical trial format.
Latest:
Breast Cancer Experts Share Obstacles and Successes as Women in OncologyDrs Graff, Mahtani, McCann, and Rugo share moments that sparked their interest in oncology and setbacks they overcame when building their careers.
Latest:
Acquisitions by 340B Hospitals Drive Up Healthcare CostsAs the 340B drug discount program has ballooned in size over the last several years, some hospitals are getting creative about how to make the program work for their own financial gain.
Latest:
Dr. Boorjian on Research With Nadofaragene Firadenovec in Nonmuscle Invasive Bladder CancerStephen A. Boorjian, MD, professor of urology, Mayo Clinic, discusses research with intravesical nadofaragene firadenovec in patients with nonmuscle invasive bladder cancer (NMIBC).
Latest:
Dr. Ansell on the Updated Analysis of ECHELON-1 in Classical Hodgkin LymphomaStephen M. Ansell, MD, PhD, discusses the updated analysis of the phase 3 ECHELON-1 in classical Hodgkin lymphoma.
Latest:
Dr. Malamud on Key Data From KATHERINE Study in HER2+ Breast CancerStephen C. Malamud, MD, associate professor, Icahn School of Medicine, Mount Sinai Health System, discusses key data from the KATHERINE study in the treatment of patients with HER2-positive breast cancer.
Latest:
Dr. Nimer on CAR T-Cell Therapy in Hematologic MalignanciesStephen D. Nimer, MD, professor of medicine, director, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses the use of chimeric antigen receptor (CAR) T-cell therapy in hematologic malignancies.
Latest:
Dr. Emerson Explains the Connection Between Stem Cell Mutations and LeukemiaStephen G Emerson, MD, PhD, Clyde Wu Professor of Immunology and Medicine, director, Herbert Irving Comprehensive Cancer Center, explains the connection between stem cell mutations and leukemia.
Latest:
Dr. Stephen Grupp on Engineered Cell Therapy for the Treatment of Pediatric ALLStephen Grupp, MD, PhD, director of translational research for the center for Childhood Cancer Research at The Children's Hospital of Philadelphia (CHOP) and medical director of the Stem Cell Laboratory at CHOP, discusses the use of engineered cell therapy for the treatment of Acute Lymphoblastic Leukemia (ALL).
Latest:
Dr. Stephen Huang on Challenges in Pediatric Thyroid CancerStephen Huang, MD, Associate Professor of Pediatrics, Harvard Medical School, Dana Farber Cancer Institute, discusses the challenges of pediatric thyroid cancer.
Latest:
Dr Freedland on the FDA Approval of Enzalutamide in nmCSPCStephen J. Freedland, MD, discusses the significance of the FDA approval of enzalutamide in nonmetastatic castration-sensitive prostate cancer.
Latest:
Dr. Johnston on the Results of monarchE With Abemaciclib in High-Risk Early Breast CancerStephen Johnston, MA, PhD, FRCP, discusses the results of the phase 3 monarchE study examining the addition of abemaciclib to endocrine therapy in patients with high-risk early hormone receptor–positive, HER2-negative breast cancer.
Latest:
Dr. Graziano on Sequencing Targeted Therapy in NSCLCStephen L. Graziano, MD, professor of medicine, division chief of medicine, and division chief of Upstate Cancer Center Adult Hematology/Oncology at the Upstate University Hospital, discusses sequencing targeted therapy for patients with non–small cell lung cancer (NSCLC).
Latest:
Future Directions in Treatment of Small Cell Lung CancerPanelists conclude their discussion by commenting on areas of unmet need and sharing personal perspectives on factors that may change clinical practice for SCLC in the future.
Latest:
Experts Highlight Their Biggest Takeaways from the 2023 SOHO Annual MeetingKey opinion leaders from across the hematologic oncology realm shared their biggest takeaways from the 2023 SOHO Annual Meeting.
Latest:
Myeloproliferative Neoplasm Management: Future Directions in CareClosing out their discussion on myeloproliferative neoplasms, key opinion leaders share excitement for future evolutions in the treatment paradigm.
Latest:
Dr. Stephen Grubbs on Measuring Value in OncologyStephen S. Grubbs, MD, senior director of the new clinical affairs department of the American Society of Clinical Oncology (ASCO) discusses value-based oncology.
